---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-000660"
form_type: "8-K"
ticker: "CNSP"
cik: "0001729427"
company_name: "CNS Pharmaceuticals, Inc."
filed_at: "2024-02-02T23:59:59+00:00"
generated_at: "2026-06-06T09:58:59.021499+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CNS Pharma raises $3.7M in $0.30/unit offering; appoints Amy Mahery to board

## Summary
- Offering of 2.2M shares, 11.1M pre-funded warrants, and 26.7M Series A & B warrants at $0.30 per unit.
- Gross proceeds ~$3.7M; net proceeds to fund CNS-201 trial and working capital.
- Amy Mahery appointed independent director as of Feb 1, 2024; Andrzej Andraczke resigned.
- Warrant amendment for 3.756M existing warrants: exercise price reduced to $0.30 if shareholder approved.

## SEC filing metadata
- accession: 0001683168-24-000660
- form_type: 8-K
- ticker: CNSP
- cik: 0001729427
- company_name: CNS Pharmaceuticals, Inc.
- filed_at: 2024-02-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1729427/000168316824000660/0001683168-24-000660-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1729427/000168316824000660/cns_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-000660
- JSON: https://secwatch.observer/filing/0001683168-24-000660.json
- Plain text: https://secwatch.observer/filing/0001683168-24-000660.txt

## Key facts
- Executive change
  Amy Mahery was appointed as Independent Director at CNS Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Independent Director
  source text: As previously reported, on January 17, 2024, the Company’s Board of Directors (the “Board”) agreed to appoint Amy Mahery as an independent member of the Company’s Board effective upon the completion of the Company’s financing.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1729427/000168316824000660/0001683168-24-000660-index.htm
- Material Agreements
  CNS Pharmaceuticals, Inc. entered into Placement Agreement with A.G.P./Alliance Global Partners and Maxim Group LLC valued at $3.7 million (effective 2024-01-29).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: A.G.P./Alliance Global Partners and Maxim Group LLC
  - Value: $3.7 million
  - Effective: 2024-01-29
  source text: On January 29, 2024, the Company entered into a placement agency agreement with A.G.P./Alliance Global Partners (“AGP”) and Maxim Group LLC (“Maxim” and collectively with AGP, the “Placement Agents”) (the “Placement Agreement”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1729427/000168316824000660/0001683168-24-000660-index.htm
- Material Agreements
  CNS Pharmaceuticals, Inc. amended Warrant Amendment (effective 2024-01-29).
  - Action: amendment
  - Effective: 2024-01-29
  source text: anuary 29, 2024, the Company entered into a warrant amendment agreement (the “Warrant Amendment”) pursuant to which the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1729427/000168316824000660/0001683168-24-000660-index.htm
- Material Agreements
  CNS Pharmaceuticals, Inc. entered into Securities Purchase Agreement with certain institutional investors (effective 2024-01-29).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional investors
  - Effective: 2024-01-29
  source text: the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors that participated in the offering
  evidence_url: https://www.sec.gov/Archives/edgar/data/1729427/000168316824000660/0001683168-24-000660-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.